Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Role of gene therapy in treatment of cancer for craniofacial regeneration-current molecular strategies, future perspectives, and challenges: a narrative review

  • Himanshu Singh (Department of Oral and Maxillofacial Pathology and Oral Microbiology, Index Institute of Dental Sciences)
  • 투고 : 2023.01.26
  • 심사 : 2023.03.30
  • 발행 : 2024.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Gene therapy involves the introduction of foreign genetic material into host tissue to alter the expression of genetic products. Gene therapy represents an opportunity to alter the course of various diseases. Hence, genetic products utilizing safe and reliable vectors with improved biotechnology will play a critical role in the treatment of various diseases in the future. This review summarizes various important vectors for gene therapy along with modern techniques for potential craniofacial regeneration using gene therapy. This review also explains current molecular approaches for the management and treatment of cancer using gene therapy. The existing literature was searched to find studies related to gene therapy and its role in craniofacial regeneration and cancer treatment. Various databases such as PubMed, Science Direct, Scopus, Web of Science, and Google Scholar were searched for English language articles using the keywords "gene therapy," "gene therapy in present scenario," "gene therapy in cancer," "gene therapy and vector," "gene therapy in diseases," and "gene therapy and molecular strategies."

키워드

참고문헌

  1. Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types : induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III.J Exp Med 1944;79:137-58.
  2. Crawford GE, Holt IE, Mullikin JC, Tai D, Blakesley R, Bouffard G, et al. Identifying gene regulatory elements by genome-wide recovery of DNase hypersensitive sites. Proc Natl Acad Sci U S A 2004;101:992-7.
  3. Omenn GS, Lane L, Lundberg EK, Beavis RC, Overall CM, Deutsch EW. Metrics for the human proteome project 2016: progress on identifying and characterizing the human proteome, including post-translational modifications. J Proteome Res 2016;15:3951-60.
  4. Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci 2018;27:233-44.
  5. Aiuti A, Bachoud-Levi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 2007;14:1555-63.
  6. Barney M. Acts & Facts. Mutations: the raw material for evolution? [Internet]. Dallas, TX: Institute for Creation Research; 2007 [cited 2023 Jan 26]. https://www.icr.org/article/mutations-raw-material-for-evolution/.
  7. Carlin JL. Mutations are the raw materials of evolution. Nature Educ Knowl 2011;3:10.
  8. Goncalves GA, Paiva RM. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo) 2017;15:369-75.
  9. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012;20:1831-2.
  10. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14: 642-62.
  11. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010;11:636-46.
  12. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADASCID: initial trial results after 4 years. Science 1995;270:475-80.
  13. Prabhakar AR, Paul JM, Basappa N. Gene therapy and its implications in dentistry. Int J Clin Pediatr Dent 2011;4:85-92.
  14. Singh A, Badni M, Singh A, Samadi FM, Kabiraj A. Gene therapy for oral cancer-journey to a new horizon. Oral Maxillofac Pathol J 2012;3:203-10.
  15. Sunil PM, Ramachandran CR, Jaisanghar N, Santhosh Kumar C. Dental surgeons as gene therapist. Int J Oral Maxillofac Pathol 2012;3:65-7.
  16. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000;60:249-71.
  17. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15:1022-33.
  18. Ramos-Kuri M, Rapti K, Mehel H, Zhang S, Dhandapany PS, Liang L, et al. Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy. Biochim Biophys Acta 2015;1853(11 Pt A):2870-84.
  19. Finegold AA, Mannes AJ, Iadarola MJ. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999;10:1251-7.
  20. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005;16:1016-27.
  21. Rochat T, Morris MA. Gene therapy for cystic fibrosis by means of aerosol. J Aerosol Med 2002;15:229-35.
  22. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72.
  23. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ 2001;164:1612.
  24. Marini B, Kertesz-Farkas A, Ali H, Lucic B, Lisek K, Manganaro L, et al. Nuclear architecture dictates HIV-1 integration site selection. Nature 2015;521:227-31.
  25. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-96.
  26. Ryan KJ, Ray CG. Sherris medical microbiology. 4th ed. New York: McGraw Hill; 2004.
  27. Johnson L, Gupta AK, Ghafoor A, Akin D, Bashir R. Characterization of vaccinia virus particles using microscale silicon cantilever resonators and atomic force microscopy. Sens Actuators B Chem 2006;115:189-97.
  28. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002;83(Pt 12):2915-31.
  29. Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF. Herpes simplex. Pediatr Rev 2009;30:119-29.
  30. Klein TM, Arentzen R, Lewis PA, Fitzpatrick-McElligott S. Transformation of microbes, plants and animals by particle bombardment. Biotechnology (N Y) 1992;10:286-91.
  31. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A 1993;90:4455-9.
  32. Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2005;2:255-68.
  33. Lurquin PF. Gene transfer by electroporation. Mol Biotechnol 1997;7:5-35.
  34. Potter H, Cooke SW. Gene transfer into adherent cells growing on microbeads. In: Change DC, editor. Guide to electroporation and electrofusion. San Diego, CA: Academic Press; 1992. p. 201-8.
  35. Hatada S, Nikkuni K, Bentley SA, Kirby S, Smithies O. Gene correction in hematopoietic progenitor cells by homologous recombination. Proc Natl Acad Sci U S A 2000;97:13807-11.
  36. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-66.
  37. Gissel H, Clausen T. Excitation-induced Ca2+ influx and skeletal muscle cell damage. Acta Physiol Scand 2001;171:327-34.
  38. Hofmann GA, Dev SB, Nanda GS, Rabussay D. Electroporation therapy of solid tumors. Crit Rev Ther Drug Carrier Syst 1999;16:523-69.
  39. Miao CH, Ye X, Thompson AR. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther 2003;14:1297-305.
  40. Indu S, Ramesh V, Oza N, Prashad KV. Gene therapy: an overview. J Orofacial Sci 2013;5:83-7.
  41. Izmirli M, Sonmez D, Gogebakan B. The war against cancer: Suicide gene therapy. Adv Mod Oncol Res 2016;2:139-49.
  42. Gaj T, Sirk SJ, Shui SL, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harb Perspect Biol 2016;8:a023754.
  43. Rossor AM, Reilly MM, Sleigh JN. Antisense oligonucleotides and other genetic therapies made simple. Pract Neurol 2018;18:126-31.
  44. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55.
  45. Le BT, Raguraman P, Kosbar TR, Fletcher S, Wilton SD, Veedu RN. Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Mol Ther Nucleic Acids 2019;14:142-57.
  46. Lundin KE, Gissberg O, Smith CI. Oligonucleotide therapies: the past and the present. Hum Gene Ther 2015;26:475-85.
  47. Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 2017;57:81-105.
  48. Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics 2018;10:65.
  49. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
  50. Schuster S, Miesen P, van Rij RP. Antiviral RNAi in insects and mammals: parallels and differences. Viruses 2019;11:448.
  51. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017;16:203-22.
  52. Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, et al. An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci 2020;240:117077.
  53. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006;2:e140.
  54. Feng J, Yang M, Wei Q, Song F, Zhang Y, Wang X, et al. Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. J Cell Mol Med 2020;24:9028-40.
  55. Xin Y, Huang M, Guo WW, Huang Q, Zhang LZ, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol Cancer 2017;16:134.
  56. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-59.
  57. Liu YP, von Eije KJ, Schopman NC, Westerink JT, ter Brake O, Haasnoot J, et al. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther 2009;17:1712-23.
  58. Moyad MA. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Urol Nurs 2007;27:256-7.
  59. Dambach MJ, Trecki J, Martin N, Markovitz NS. Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther 2006;13:891-8.
  60. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141-8.
  61. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005;30:71-88.
  62. Lin X, Huang H, Li S, Li H, Li Y, Cao Y, et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007;6:648-53.
  63. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999;5:1715-22.
  64. Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS, et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004;114:1871-9.
  65. O'Malley BW Jr, Li D, McQuone SJ, Ralston R. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 2005;115:391-404.
  66. Nakashima M, Iohara K, Zheng L. Gene therapy for dentin regeneration with bone morphogenetic proteins. Curr Gene Ther 2006;6:551-60.
  67. Rabie AB, Dai J, Xu R. Recombinant AAV-mediated VEGF gene therapy induces mandibular condylar growth. Gene Ther 2007;14:972-80.
  68. Kaigler D, Cirelli JA, Giannobile WV. Growth factor delivery for oral and periodontal tissue engineering. Expert Opin Drug Deliv 2006;3:647-62.
  69. Jin Q, Anusaksathien O, Webb SA, Printz MA, Giannobile WV. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. Mol Ther 2004;9:519-26.
  70. Franceschi RT. Biological approaches to bone regeneration by gene therapy. J Dent Res 2005;84:1093-103.
  71. Aframian DJ, Palmon A. Current status of the development of an artificial salivary gland. Tissue Eng Part B Rev 2008;14:187-98.
  72. Melvin JE, Yule D, Shuttleworth T, Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol 2005;67:445-69.
  73. Tran SD, Sugito T, Dipasquale G, Cotrim AP, Bandyopadhyay BC, Riddle K, et al. Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland. Tissue Eng 2006;12:2939-48.
  74. Baum BJ, Zheng C, Cotrim AP, Goldsmith CM, Atkinson JC, Brahim JS, et al. Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochim Biophys Acta 2006;1758:1071-7.
  75. Purdue GF, Hunt JL, Still JM Jr, Law EJ, Herndon DN, Goldfarb IW, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997;18(1 Pt 1):52-7.
  76. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds: a clinical experience. Dermatol Surg 1995;21:839-43.
  77. Tristan-Manzano M, Justicia-Lirio P, Maldonado-Perez N, Cortijo-Gutierrez M, Benabdellah K, Martin F. Externally-controlled systems for immunotherapy: from bench to bedside. Front Immunol 2020;11:2044.
  78. Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol 2017;18:1-15.
  79. Sostoa J, Dutoit V, Migliorini D. Oncolytic viruses as a platform for the treatment of malignant brain tumors. Int J Mol Sci 2020;21:7449.
  80. Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther 2018;29:160-79.
  81. Xia Y, Li X, Sun W. Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China. Curr Gene Ther 2020;20:127-41.
  82. Shahryari A, Saghaeian Jazi M, Mohammadi S, Razavi Nikoo H, Nazari Z, Hosseini ES, et al. Development and clinical translation of approved gene therapy products for genetic disorders. Front Genet 2019;10:868.
  83. Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol 2018;7:16.
  84. Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study using Rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Mol Ther Oncolytics 2018;12:56-67.
  85. Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther 2010;10:819-32.
  86. Pettitt D, Arshad Z, Smith J, Stanic T, Hollander G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther 2018;26:342-53.
  87. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev 2016;30:157-67.
  88. Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc) 2017;53:597-608.
  89. Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist 2020;25:e138-46.
  90. Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res 2019;25:1702-8.
  91. Hoogendoorn KH. Advanced therapies: clinical, non-clinical and quality considerations. In: Nadkarni S, editor. Pharmaceutical biotechnology. Delhi, India: Swastik Publishers & Distributors; 2019. p. 357.
  92. Mohty M, Labopin M, Velardi A, van Lint MT, Bunjes D, Bruno B, et al. Allogeneic genetically modified T cells (HSV-TK) as adjunctive treatment in haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) of adult patients with high-risk hematological malignancies: a pair-matched analysis from the acute Leukemia working party of EBMT. Blood 2016;128:672.
  93. Chattopadhyay S, Sen GC. Tyrosine phosphorylation in tall-like receptor signaling. Cytokine Growth Factor Rev 2014;25:533-41.
  94. Chattopadhyay S, Sen GC. RIG-I-like receptor-induced IRF3 mediated pathway of apoptosis (RIPA): a new antiviral pathway. Protein Cell 2017;8:165-8.
  95. Stolberg SG. The biotech death of Jesse Gelsinger. N Y Times Mag 1999 Nov 28: section 6, 136-40, 149-50.
  96. Suwanmanee T, Ferris MT, Hu P, Gui T, Montgomery SA, Pardo-Manuel de Villena F, et al. Toward personalized gene therapy: characterizing the host genetic control of lentiviral-vector-mediated hepatic gene delivery. Mol Ther Methods Clin Dev 2017;5:83-92.